Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1967967 | 0.98 | GNAI3 (0.41) | MGAMGAASIMGAM2POLB | |
| SCHEMBL8414225 | 0.93 | POLB (0.41) | MGAMGAASIMGAM2POLB | |
| SCHEMBL15930224 | 0.89 | SLC6A1 (0.56) | MGAMGAASIMGAM2POLB | |
| Trifluoroacetic Acid SCHEMBL7425259 | 0.89 | SLC6A1 (0.38) | MGAMGAASIMGAM2POLB | |
| Hydrochloric Acid SCHEMBL6102502 | 0.87 | SLC6A1 (0.55) | MGAMGAASIMGAM2POLB | |
| Hydrochloric Acid SCHEMBL30455767 | 0.87 | SLC6A1 (0.55) | MGAMGAASIMGAM2POLB | |
| SCHEMBL2721040 | 0.86 | — | — | |
| SCHEMBL9974687 | 0.85 | GNAI3 (0.40) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL27086500 | 0.84 | POLB (0.37) | MGAMGAASIMGAM2POLB | |
| SCHEMBL12883653 | 0.84 | POLB (0.43) | POLBALDH1A1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868030-A | Preparation method of 1- (1-tert-butyloxycarbonyl-4-piperidylacetyl) -4-methylsulfonyloxypiperidine and 1- (1-tert-butyloxycarbonyl-4-piperidylacetyl) -4-methylsulfonyloxypiperidine | 有机合成药品工业株式会社 | 2020-10-30 | — | — | CN | claimed |
| EP-1817032-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006058294-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | claimed |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-5112825-A | Antirhinoviral heteroamine-substituted pyridazines | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-05-12 | — | — | US | disclosed |
| US-5100893-A | Viricides, effective against picorna virus, durability | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-03-31 | — | — | US | disclosed |
| WO-1991010651-A1 | ANTICHOLINERGIC AGENTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
| EP-0435381-A1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-03 | — | — | EP | disclosed |
| EP-0398427-A1 | Antirhinoviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-22 | — | — | EP | disclosed |
| EP-0037713-B1 | NOVEL 1,3-DIHYDRO-1-((1-PIPERIDINYL)ALKYL)-2H-BENZIMIDAZOL-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-02-08 | — | — | EP | disclosed |
| EP-0037713-A1 | Novel 1,3-dihydro-1-((1-piperidinyl)alkyl)-2H-benzimidazol-2-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-10-14 | — | — | EP | disclosed |
| US-4289772-A | PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 1981-09-15 | — | — | US | disclosed |
| US-4254127-A | ANTIEMETIC, NEUROLIPTIC AND ANTICONGESTIVE AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | MGAM 140/4885GAA 4/4885SI 167/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | MGAM 1430/4885GAA 791/4885SI 3072/4885 |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | SMARCC1, SMARCC2, SMARCA1 | MGAM 2269/4885GAA 1201/4885SI 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.